Status:
WITHDRAWN
A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Painful Diabetic Neuropathy
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if analgesic efficacy can be detected with single dose administration in patients with chronic neuropathic pain due to painful diabetic neuropathy.
Eligibility Criteria
Inclusion
- Patient has been treated for type 1 or 2 diabetes mellitus with glycosylated hemoglobin
- Patient has pain in both feet that occurred after onset of diabetes
- Patient agrees to maintain a consistent activity level throughout the study
- Patient is not on chronic pain therapy, or is on a stable dose of one pain therapy
- Female patients of reproductive potential must agree to use two acceptable methods of birth control through out the study
- Patients taking a pain medication must be on a stable dose at least 1 month prior to participating in study
Exclusion
- Patient has a history of congestive heart failure
- Patient has/had a seizure disorder
- Patient has tried and failed 3 or more drugs to treat neuropathic pain
- Patient is currently taking pregabalin or duloxetine hydrochloride
- Patient has had a malignancy within the past 2 years (excluding basal cell carcinoma)
- Patient has history of hepatitis B or C or HIV infection
- Patient has skin-condition that may decrease sensitivity in area of neuropathic pain
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00837941
Start Date
April 1 2009
End Date
September 1 2009
Last Update
July 27 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.